Dr. Block is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2008 - 2011
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2005 - 2008
- Mayo Clinic College of MedicineClass of 2005
Certifications & Licensure
- MN State Medical License 2006 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2012 Jul 24
- Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Start of enrollment: 2014 Apr 14
Publications & Presentations
PubMed
- 46 citationsPhase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancersGerardo Colon-Otero, Valentina Zanfagnin, Xiaonan Hou, Nathan R. Foster, Erik Asmus
ESMO Open. 2020-10-01 - 60 citationsT cell Bim levels reflect responses to anti–PD-1 cancer therapyRoxana S. Dronca, Xin Liu, Susan M. Harrington, Lingling Chen, Siyu Cao
JCI Insight. 2016-05-05 - 127 citationsImmune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.Anupam Kotwal, Candace L. Haddox, Matthew S. Block, Yogish C. Kudva
BMJ Open Diabetes Research & Care. 2019-02-01
Press Mentions
- What You Should Know About Ovarian Cancer VaccinesNovember 16th, 2024
- Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer VaccineNovember 22nd, 2021
- Summer Sun Safety TipsSeptember 3rd, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: